BioWorld

May 19, 2004

View Archived Issues

Celltech Agrees To Buyout By UCB For $2.7B In Cash

LONDON - Celltech Group plc, the UK's largest biotechnology company, has agreed to be taken over by UCB SA, of Brussels, Belgium, in an all-cash deal that values Celltech at about £1.5 billion (US$2.7 billion). (BioWorld Today) Read More

Chiron's Failed Sepsis Drug Taking On CAP In Phase III

Read More

FDA: Critical Path Initiative' Sharpens Drug Development

Read More

Pozen Starts Phase III Migraine Program, Hits $15M Milestone

Read More

Neose Offering Brings In $34M For EPO, G-CSF Development

Read More

Panacos Attracts $18.3M Round To Fund HIV Drug Development

Read More

Other News To Note

Read More